Haloperidol Cf (Haloperidol)

Haloperidol Cf is prescribed for several psychiatric disorders where dopamine blockade is beneficial.

• Management of schizophrenia, including acute exacerbations.
• Treatment of acute psychotic episodes unrelated to schizophrenia.
• Control of manic episodes in bipolar disorder.
• Reduction of motor and vocal tics associated with Tourette syndrome.
• Adjunct therapy for severe agitation or aggression when other options are insufficient.

Haloperidol Cf may cause a range of side effects that vary in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor or rigidity.
• Dry mouth and blurred vision.
• Constipation or gastrointestinal discomfort.
• Weight gain or increased appetite.
• Orthostatic hypotension leading to dizziness.

Serious

• Neuroleptic malignant syndrome, a potentially life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary facial movements.
• Severe cardiac arrhythmias, including QT prolongation.
• Hyperprolactinemia causing menstrual disturbances or galactorrhea.
• Significant depression or suicidal thoughts.
• Allergic reactions such as rash, swelling, or anaphylaxis.

Before initiating Haloperidol Cf, clinicians should assess patient history and monitor for specific risks.

• Evaluate cardiovascular status, especially for QT interval prolongation.
• Screen for a personal or family history of movement disorders.
• Use caution in patients with hepatic or renal impairment.
• Monitor blood glucose and lipid levels in patients at risk for metabolic changes.
• Assess for signs of depression or suicidal ideation during treatment.
• Discuss potential pregnancy and lactation considerations with women of childbearing age.
• Regularly review the need for continued therapy to avoid long‑term adverse effects.

Haloperidol Cf can interact with several drug classes, influencing its safety and effectiveness.

Avoid

• Other dopamine antagonists or antipsychotics that may increase extrapyramidal risk.
• Medications that prolong the QT interval, such as certain antiarrhythmics and macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants, including benzodiazepines and alcohol, which can enhance sedation.
• Anticholinergic agents that may mask extrapyramidal symptoms.
• CYP2D6 substrates (e.g., metoprolol) as haloperidol may affect their metabolism.